Literature DB >> 25299749

Age cohort differences in illicit drug use and hepatitis C among African American substance users.

Nicole Ennis Whitehead1, Lauren Hearn, Rebecca C Trenz, Larry E Burrell, William W Latimer.   

Abstract

Identifying prognostic indicators for undiagnosed Hepatitis C is crucial to attenuate the negative impact of this disease. This study explored the influence of recent and more distal injection drug use on biologically confirmed Hepatitis C infection among a sample (N = 260) of older and younger African Americans. Data from the baseline assessment of the NEURO-HIV epidemiologic study was analyzed using confounder adjusted regression techniques. Older adults were more likely to test positive for Hepatitis C (OR = 2.80, 95% CI = 1.53-5.11) due to lifetime injection drug use (AOR = 5.37, 95% CI = 3.10-9.28). Clinical implications are discussed.

Entities:  

Keywords:  Hepatitis C; medically underserved; older adult; substance use

Mesh:

Year:  2014        PMID: 25299749      PMCID: PMC4275342          DOI: 10.1080/10550887.2014.969605

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  28 in total

1.  Restricted access to care: the role of race, managed care, and type of insurance.

Authors:  Samuel L Brown; Len O'Connell
Journal:  J Health Care Finance       Date:  2004

Review 2.  The burden of hepatitis C in the United States.

Authors:  W Ray Kim
Journal:  Hepatology       Date:  2002-11       Impact factor: 17.425

3.  Latent classes of heroin and cocaine users predict unique HIV/HCV risk factors.

Authors:  P T Harrell; B E Mancha; H Petras; R C Trenz; W W Latimer
Journal:  Drug Alcohol Depend       Date:  2011-10-24       Impact factor: 4.492

4.  Management of hepatitis C patients by primary care physicians in the USA: results of a national survey.

Authors:  T M Shehab; S S Sonnad; A S Lok
Journal:  J Viral Hepat       Date:  2001-09       Impact factor: 3.728

5.  Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area.

Authors:  H Thiede; H Hagan; C S Murrill
Journal:  J Urban Health       Date:  2000-09       Impact factor: 3.671

Review 6.  Viral hepatitis in minority America.

Authors:  Renard A Rawls; Kenneth J Vega
Journal:  J Clin Gastroenterol       Date:  2005-02       Impact factor: 3.062

Review 7.  Chronic hepatitis C virus infection in older adults.

Authors:  Esther-Lee Marcus; Ran Tur-Kaspa
Journal:  Clin Infect Dis       Date:  2005-10-27       Impact factor: 9.079

8.  Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group.

Authors:  K R Reddy; J H Hoofnagle; M J Tong; W M Lee; P Pockros; E J Heathcote; D Albert; T Joh
Journal:  Hepatology       Date:  1999-09       Impact factor: 17.425

9.  Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1998-10-16

10.  Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites.

Authors:  Andrew J Muir; Jeffrey D Bornstein; Paul G Killenberg
Journal:  N Engl J Med       Date:  2004-05-27       Impact factor: 91.245

View more
  3 in total

1.  Alcohol Use Severity and Sexual Risk Behavior Among Female Substance Users.

Authors:  Rebecca C Trenz; Michael Scherer; Nicole Ennis Whitehead; William W Latimer
Journal:  Subst Use Misuse       Date:  2016-08-03       Impact factor: 2.164

2.  Prospective Longitudinal Substance Use Patterns in Patients Preparing for Hepatitis C Treatment.

Authors:  Carol S North; David E Pollio; Omar T Sims; Mamta K Jain; Barry A Hong
Journal:  J Dual Diagn       Date:  2018-01-18

Review 3.  Ageing and older people who use illicit opioids, cocaine or methamphetamine: a scoping review and literature map.

Authors:  Camille Zolopa; Stine B Høj; Nanor Minoyan; Julie Bruneau; Iuliia Makarenko; Sarah Larney
Journal:  Addiction       Date:  2022-02-10       Impact factor: 7.256

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.